246 related articles for article (PubMed ID: 12202904)
41. Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro.
Treves AJ; Cohen IR; Feldman M
J Natl Cancer Inst; 1975 Mar; 54(3):777-80. PubMed ID: 1123855
[TBL] [Abstract][Full Text] [Related]
42. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
43. Anti-metastatic activity induced by the in vivo activation of purified protein derivative (PPD)-recognizing Th1 type CD4+ T cells.
Shinomiya Y; Harada M; Kurosawa S; Okamoto T; Terao H; Matsuzaki G; Shirakusa T; Nomoto K
Immunobiology; 1995 Aug; 193(5):439-55. PubMed ID: 8522359
[TBL] [Abstract][Full Text] [Related]
44. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
45. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
[TBL] [Abstract][Full Text] [Related]
46. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
Søndergaard H; Frederiksen KS; Thygesen P; Galsgaard ED; Skak K; Kristjansen PE; Odum N; Kragh M
Cancer Immunol Immunother; 2007 Sep; 56(9):1417-28. PubMed ID: 17285290
[TBL] [Abstract][Full Text] [Related]
47. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
48. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
Konjević G; Jović V; Jurisić V; Radulović S; Jelić S; Spuzić I
Clin Exp Metastasis; 2003; 20(7):647-55. PubMed ID: 14669796
[TBL] [Abstract][Full Text] [Related]
49. [Interferon therapy in malignant melanoma].
Stadler R; Garbe C
Z Hautkr; 1990 May; 65(5):504-7. PubMed ID: 1696048
[TBL] [Abstract][Full Text] [Related]
50. [Treatment of malignant melanoma with dinitrochlorobenzene ointment].
Loth H; Ehring F
Hautarzt; 1978 Mar; 29(3):141-6. PubMed ID: 640834
[TBL] [Abstract][Full Text] [Related]
51. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
[TBL] [Abstract][Full Text] [Related]
52. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner.
Werthmöller N; Frey B; Wunderlich R; Fietkau R; Gaipl US
Cell Death Dis; 2015 May; 6(5):e1761. PubMed ID: 25973681
[TBL] [Abstract][Full Text] [Related]
53. Mechanoluminescence: an assay for lymphocyte analysis in neoplasia.
Orel VE; Alekseyev SB; Grinevich YA
J Biolumin Chemilumin; 1992 Oct; 7(4):239-44. PubMed ID: 1442175
[TBL] [Abstract][Full Text] [Related]
54. Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha.
Young MR; McCloskey G; Wright MA; Pak AS
Cancer Immunol Immunother; 1994 Jan; 38(1):9-15. PubMed ID: 8299123
[TBL] [Abstract][Full Text] [Related]
55. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma.
Strobbe LJ; Hart AA; Rümke P; Israels SP; Nieweg OE; Kroon BB
Melanoma Res; 1997 Dec; 7(6):507-12. PubMed ID: 9464624
[TBL] [Abstract][Full Text] [Related]
56. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
57. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
59. Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.
Wei H; Zheng X; Lou D; Zhang L; Zhang R; Sun R; Tian Z
Mol Immunol; 2005 May; 42(9):1023-31. PubMed ID: 15829292
[TBL] [Abstract][Full Text] [Related]
60. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy.
Stagg J; Lejeune L; Paquin A; Galipeau J
Hum Gene Ther; 2004 Jun; 15(6):597-608. PubMed ID: 15212718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
